eligibility_summary
Adults ≥18 with R/R AML (incl PIF, early relapse <6 mo, refractory relapse, ≥5% marrow or ≥1% blood blasts), R/R MDS‑EB2 (10–19% blasts) after HMA, or R/R CMML after HMA, ECOG 0–2, life expectancy ≥12 wks, adequate organs, consent and contraception. Exclude APL/CML‑AP/BC, CNS disease/involvement, pregnancy, serious cardiac/pulmonary disease or O2 need, recent live vaccine/investigational tx, unrecovered prior‑tx toxicity, recent HSCT/active GvHD, prior CAR‑T, solid organ transplant, other active malignancy, severe allergy, uncontrolled infection, HIV, active HBV/HCV (unless undetectable), or confounding/psychiatric issues.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 1, open-label, single-arm trial of NC525 in relapsed/refractory AML, MDS-EB2, and CMML. Intervention: NC525, a monoclonal antibody immunotherapy that binds and blocks LAIR-1 (CD305), an inhibitory immune checkpoint receptor. Mechanism: antagonizes LAIR-1’s collagen/C1q-triggered ITIM signaling (via SHP-1/2), aiming to lift immune suppression and potentially directly impact LAIR-1–expressing leukemic blasts/stem-progenitors. Target cells/pathways: LAIR-1 on T cells, NK cells, monocytes/macrophages, dendritic cells, and malignant myeloid cells, downstream inhibitory pathways that restrain activation, cytotoxicity, and myeloid differentiation. Status: terminated for limited clinical activity and program reprioritization.